| Literature DB >> 32587450 |
Chong-Chong Gao1, Jia Li1, Feng Cao1, Xiao-Hui Wang1, Ang Li1, Zhe Wang1, Fei Li2.
Abstract
BACKGROUND: In recent decades, an increasing number of patients have received minimally invasive intervention for infected pancreatic necrosis (IPN) because of the benefits in reducing postoperative multiple organ failure and mortality. However, there are limited published data regarding infection recurrence after treatment of this patient population. AIM: To investigate the incidence and prediction of infection recurrence following successful minimally invasive treatment in IPN patients.Entities:
Keywords: C-reactive protein; Drainage; Infection recurrence; Infectious pancreatic necrosis; Minimally invasive intervention; Procalcitonin
Mesh:
Substances:
Year: 2020 PMID: 32587450 PMCID: PMC7304114 DOI: 10.3748/wjg.v26.i22.3087
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Summary of minimally invasive treatment performed for 178 patients with infectious pancreatic necrosis
| PCD | 35 | 19.66 |
| VARD | 35 | 19.66 |
| LATOD | 18 | 10.11 |
| PCD + VARD/LATOD | 78 | 43.82 |
| VARD + LATOD | 4 | 2.25 |
| PCD + LPD | 3 | 1.69 |
| PCD + VARD + LATOD | 5 | 2.81 |
| Total | 178 | 100 |
PCD: Percutaneous catheter drainage; VARD: Video-assisted retroperitoneal debridement; LATOD: Laparoscopic-assisted transomental debridement; LPD: Laparoscopic pancreatic debridement.
Demographics of patients who underwent minimally invasive treatment for infectious pancreatic necrosis
| Age in yr | 53 ± 1 | 56 ± 4 | 0.435 |
| Male sex, | 96 (61.54) | 6 (46.15) | 0.128 |
| Smoke, | 54 (34.62) | 5 (38.46) | 0.224 |
| Alcohol, | 24 (15.38) | 0 (0) | 0.126 |
| Medical history, | |||
| Pancreatitis | 27 (17.31) | 1 (7.69) | 0.243 |
| Cardiovascular Disease | 10 (6.41) | 2 (15.38) | 0.180 |
| Diabetes | 3 (1.92) | 1 (7.69) | 0.246 |
| Renal disease | 8 (5.13) | 0 (0) | 0.520 |
| Liver disease | 14 (8.97) | 0 (0) | 0.311 |
| BMI in kg/m2 | 23.63 ± 0.13 | 23.99 ± 0.43 | 0.430 |
Quantitative data are presented as the mean ± standard error of the mean. BMI: Body mass index.
Clinical characteristics of patients who underwent minimally invasive treatment for infectious pancreatic necrosis
| Time onset of IPN in d | 53 ± 1 | 55 ± 5 | 0.796 |
| Cause of IPN, | |||
| Biliary | 92 (58.97) | 6 (46.15) | 0.543 |
| Alcohol | 23 (14.74) | 3 (23.08) | 0.136 |
| Idiopathic | 5 (3.21) | 1 (7.69) | 0.386 |
| Hypertriglyceridemia | 36 (23.08) | 3 (23.08) | 1.000 |
| BISAP score | 3.53 ± 0.05 | 3.62 ± 0.14 | 0.632 |
| APACHE II score | 9.56 ± 0.18 | 8.92 ± 0.40 | 0.328 |
| Impaired mental status, | 21 (13.46) | 2 (15.38) | 0.302 |
| SIRS, | 146 (93.59) | 12 (92.31) | 0.395 |
| Pre-operative blood test | |||
| WBC as 109/L | 14.59 ± 0.28 | 15.32 ± 0.60 | 0.466 |
| BUN in mmol/L | 10.45 ± 0.50 | 9.09 ± 0.97 | 0.440 |
| Creatinine in µmol/L | 156.86 ± 9.09 | 115.61 ± 10.60 | 0.195 |
| CRP in mg/L | 66.47 ± 5.63 | 42.66 ± 10.44 | 0.230 |
| IL-6 in pg/mL | 62.25 ± 7.79 | 53.05 ± 8.45 | 0.735 |
| Procalcitonin in ng/mL | 2.44 ± 0.19 | 2.29 ± 0.55 | 0.823 |
| Minimally invasive treatment | 0.157 | ||
| Sole treatment with PCD/VARD/LATOD, | 86 (55.13) | 4 (30.77) | |
| Combined treatment, | 70 (44.87) | 9 (69.23) | |
| Post treatment blood test | |||
| WBC as 109/L | 7.37 ± 0.21 | 11.00 ± 0.61 | 0.000 |
| BUN in mmol/L | 6.89 ± 0.21 | 6.92 ± 0.75 | 0.974 |
| Creatinine in µmol/L | 86.82 ± 2.78 | 74.85 ± 7.46 | 0.227 |
| CRP in mg/L | 7.68 ± 0.54 | 18.97 ± 3.84 | 0.000 |
| IL-6 in pg/mL | 8.28 ± 0.68 | 18.76 ± 4.24 | 0.000 |
| Procalcitonin in ng/mL | 0.04 ± 0.01 | 0.09 ± 0.01 | 0.000 |
| Duration of drainage in d | 79 ± 3 | 104 ± 13 | 0.025 |
| Catheter length in cm | 7.13 ± 0.26 | 10.68 ± 0.66 | 0.000 |
Abnormally higher than normal range. Quantitative data are presented as the mean ± standard error of the mean. IPN: Infectious pancreatic necrosis; BISAP: Bedside index for severity in acute pancreatitis; APACHE II: Chronic Health Evaluation II; SIRS: Systemic inflammatory response syndrome; WBC: White blood cell; BUN: Blood urea nitrogen; CRP: C-reactive protein.
Bivariate and multivariate correlation analysis to identify factors associated with infection recurrence after drainage catheter removal
| WBC | 0.328 | 0.661 | 8.622 | 0.003 |
| CRP | 0.265 | 0.205 | 7.74 | 0.005 |
| IL-6 | 0.192 | 0.075 | 2.247 | 0.134 |
| Procalcitonin | 0.327 | 24.779 | 4.533 | 0.033 |
| Duration of drainage | 0.159 | 0.011 | 0.712 | 0.399 |
| Catheter length | 0.277 | 0.589 | 6.032 | 0.014 |
WBC: White blood cell; CRP: C-reactive protein; IL-6: Interleukin-6.
Figure 1Receiver operating characteristic curves of the values for white blood cell, serum C-reactive protein, and procalcitonin measured after catheter removal, and length of the catheter measured by computerized tomography scan. WBC: White blood cell; CRP: C-reactive protein; PCT: Procalcitonin; IAP: Intra-abdominal pressure.
Cut-off value and ability of independent risk factors to predict infection recurrence
| WBC as 109/L | × 0.856 (0.739-0.972) | 0.000 | 9.95 | 0.77 | 0.83 |
| CRP in mg/L | 0.787 (0.670-0.904) | 0.001 | 7.37 | 0.77 | 0.62 |
| PCT in ng/mL | 0.854 (0.767-0.941) | 0.000 | 0.05 | 0.85 | 0.75 |
| Catheter length in cm | 0.800 (0.699-0.900) | 0.000 | 8.05 | 0.85 | 0.61 |
CI: Confidence interval; WBC: White blood cell; CRP: C-reactive protein; PCT: Procalcitonin.